Publications & News

WilmerHale Counsels Aquinnah Pharmaceuticals in $10M Investment From Pfizer and AbbVie

April 25, 2017

Aquinnah Pharmaceuticals, a privately held biotechnology company focused on RNA binding proteins for neurodegenerative disease, announced that two additional pharmaceutical companies, Pfizer Inc. and AbbVie Inc., have invested in their work to treat Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. This $10 million adds to an earlier $5 million investment, that WilmerHale also handled, made by Takeda Pharmaceuticals in December 2015.

The WilmerHale team counseling Aquinnah Pharmaceuticals included Joshua Fox and Stephanie Singer.

Read Aquinnah Pharmaceuticals' press release for more information.